Featured Studies

Researchers from the National Cancer Institute at the NIH Clinical Center are currently looking for patients who have HER2-expressing endometrial cancer. The purpose of the study is to test two investigational study drugs, a vaccine that targets HER2 (AdHER2DC) and a drug that is expected to improve immune cell function (N-803). These study drugs will be used with pembrolizumab and lenvatinib which are FDA approved to treat endometrial cancer.

Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

Researchers want to see if they can measure the amount of anti-cancer drug, Abemaciclib in a brain tumor and brain fluid after a patient has taken this drug for a few days. These findings can help explain how much drug gets into the brain and how drugs work to shrink high grade gliomas to improve outcomes for these patients.

Researchers at the National Cancer Institute (NCI) are conducting a clinical trial to study new imaging techniques for those with HCC. Pictures (Images) are taken with a positron emission tomography (PET) using a new investigational imaging radiotracer, 18 F-DCFPyL. Our research study focus is to see if this tracer will improve images taken of your liver to identify HCC tumors earlier in the disease process. We will also determine if we can see differences between treated tumors and the development of new tumors.

National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

Investigators at the National Cancer Institute (NCI) are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.